| Name | Title | Contact Details |
|---|
Phoenix Data Systems, Inc. is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Flexion Therapeutics (NASDAQ: FLXN) is a biopharmaceutical company focused on the discovery, development & commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions. Flexion is based in Burlington, Massachusetts.
Founded by identical twins, Rose Cook and Lynn Faughey, The FlexPro Group is a specialty consulting firm, focused on delivering project management expertise to companies in the Life Sciences. Since 2008, FlexPro has been recognized as a premier provider of project management consulting services to this industry. For the 3rd year in a row, FlexPro was recognized by Inc. Magazine as one of America`s fastest-growing private companies: #859 (2014), #288 (2013) and #104 (2012). Also ranked 6th on the Philadelphia 100 lists of fastest growing privately-held companies (both in 2013 and 2012). Ranked among the Top 25 Management Consulting Firms in Philadelphia Business Journal`s "The List" (2017).
Happify Health designs and deploys highly engaging software that can improve mental health, physical health, and well-being across the continuum of care. And we bring all sides of healthcare together, in partnership with leading enterprises, pharma, health plans, and healthcare clients around the world.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.